NDA 215390 is the FDA application for IGALMI (dexmedetomidine hydrochloride). The FDA's Orange Book lists the applicant of record as TEVA NEUROSCIENCE INC and the first approval on it as Apr 5, 2022. Code name used in development: BXCL501. Owner today: Teva Pharmaceutical Industries Ltd. (NYSE/TASE: TEVA).
Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 215390 · Orange Book NDA 215390
| Brand name (FDA) | IGALMI Orange Book trade name: IGALMI |
|---|---|
| Active ingredient (FDA) | DEXMEDETOMIDINE HYDROCHLORIDE |
| Code name | BXCL501 Source: BioXcel Therapeutics 10-K, Mar 27, 2026 “BXCL501 (currently marketed and commercialized as IGALMI)” |
| FDA applicant of record | TEVA NEUROSCIENCE INC FDA Orange Book data files as of Nov 13, 2026 |
|---|---|
| Owner today | Teva Pharmaceutical Industries Ltd. (TEVA) Source: Teva press release, Nov 16, 2026 “a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)” … “Teva acquired IGALMI in late October 2026.” |
| Earlier / partner | BioXcel Therapeutics (ticker at the time: BTAI): sold the product to the current owner, Oct 26, 2026 Source: BioXcel Therapeutics 8-K, Oct 30, 2026 “On October 26, 2026, the Debtors completed the Sale, pursuant to which Teva acquired” … “BTAI” |
| No. | Trade name | Form; route | Strength | Approved |
|---|---|---|---|---|
| 001 | IGALMI | FILM;BUCCAL, SUBLINGUAL | EQ 0.12MG BASE | Apr 5, 2022 |
| 002 | IGALMI | FILM;BUCCAL, SUBLINGUAL | EQ 0.18MG BASE | Apr 5, 2022 |
Drug page: /drug/igalmi
Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.